comprehensive -WSS

comprehensive

author：explore 2025-09-30 23:40:44 - browse：4

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： NYU Langone launches private ChatGPT for its health care data

WSS

The EU Joint Clinical Assessment needs to live up to its promise

2023 STAT Wunderkinds: get to know the winners

Researchers explore possible ties between long Covid, menopause

First Opinion Podcast: Long Covid needs a new approach

STAT Summit: Biotech founders on deal

Lawmakers consider Medicare pay reforms for doctors

leisure time

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

What does generative AI mean for health care? We asked experts

FDA panel gives mixed vote on blood pressure devices

Activists slam private health insurers over coverage restrictions

Diversity in medical illustrations gets boost from Chidiebere Ibe

Anesthesiologist group: stop taking Ozempic before surgery

NYU Langone launches private ChatGPT for its health care data

Novavax promises a turnaround & Lilly roils the obesity market

In science, is the line between industry and academia shifting?

After affirmative action ruling, medical educators look to 'holistic review'

NYU Langone launches private ChatGPT for its health care data

entertainment

CDC advisory panel says seniors 'may' get RSV vaccine

Researchers explore possible ties between long Covid, menopause

Apellis safety probe of eye disease drug centers on injection needle

AstraZeneca challenges Medicare drug negotiation program

Why health workers in Gaza are injured or die at high rates

NYU Langone launches private ChatGPT for its health care data

hotspot

leisure time

focus

entertainment